-+ 0.00%
-+ 0.00%
-+ 0.00%

MetaVia Presents Phase 2a Data at EASL 2025 Showing DA-1241, A GPR119 Agonist, Significantly Lowers ALT And Liver Fat An Presumed MASH Patients

Benzinga·05/07/2025 07:12:07
Listen to the news
  • DA-1241 Significantly Decreased Plasma ALT levels, with a Mean Reduction of 22.8 U/L After 16 Week-Treatment
  • Controlled Attenuation Parameter (CAP) Score Improved by 23.0 dB/m, Indicating Reduced Liver Fat Content
  • Improvement in Systemic Inflammatory and Fibrosis Biomarkers Supports Beneficial Effects on Liver Health